Gout arthritis (GA) is a painful inflammatory disease in response to
monosodium urate (MSU) crystals in the joints. 15deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is a natural activator of
PPAR-γ with
analgesic, anti-inflammatory, and pro-resolution properties. Thus, we aimed to evaluate the effect and mechanisms of action of
15d-PGJ2 nanocapsules (NC) in the model of GA in mice, since a reduction of 33-fold in the dose of
15d-PGJ2 has been reported. Mice were treated with 15d-PGJ2-loaded NC, inert NC, free
15d-PGJ2 (without NC), or 15d-PGJ2-loaded NC+
GW9662, a
PPAR-γ inhibitor. We show that 15d-PGJ2-loaded NC provided
analgesic effect in a dose that the free
15d-PGJ2 failed to inhibiting
pain and
inflammation. Hence, 15d-PGJ2-loaded NC reduced MSU-induced IL-1β, TNF-α,
IL-6,
IL-17, and
IL-33 release and oxidative stress. Also, 15d-PGJ2-loaded NC decreased the maturation of IL-1β in LPS-primed BMDM triggered by MSU. Further, 15d-PGJ2-loaded NC decreased the expression of the components of the
inflammasome Nlrp3, Asc, and
Pro-caspase-1, as consequence of inhibiting NF-κB activation. All effects were
PPAR-γ-sensitive. Therefore, we demonstrated that 15d-PGJ2-loaded NC present
analgesic and anti-inflammatory properties in a
PPAR-γ-dependent manner inhibiting IL-1β release and NF-κB activation in GA. Concluding, 15d-PGJ2-loaded NC ameliorates MSU-induced GA in a
PPAR-γ-sensitive manner.